Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Big shoes: Davis needs to fill Merck’s post-Keytruda pipeline as Frazier shifts to executive chair

Focus will be on modest, early-stage deals as the pharma seeks next blockbuster

By Virginia Li, Associate Editor
February 5, 2021 2:30 AM UTC

As Merck’s Robert Davis prepares to take the helm as CEO, his primary challenge will be executing on a pipeline robust enough to carry the pharma over Keytruda’s coming patent cliff. 

Chairman and CEO Ken Frazier will step down on June 30 and hand over the reins to Davis, who is EVP, global services and CFO. Frazier will stay on as executive chairman through a to-be-determined transition period. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Merck & Co. Inc.